Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Solid Tumors
Interventions
DRUG

Doxil

Starting dose of 20 mg/m\^2 IV over 2 hours on Day 1, 21 day cycle

DRUG

Gemcitabine

500 mg/m\^2 IV over 30 minutes on Days 1 and 8, 21 day cycle

DRUG

Velcade

Starting dose of 0.7 mg/m\^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00500422 - Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | Biotech Hunter | Biotech Hunter